AU2002225772A1 - Therapeutic agents and methods of use thereof for treating an amyloidogenic disease - Google Patents

Therapeutic agents and methods of use thereof for treating an amyloidogenic disease

Info

Publication number
AU2002225772A1
AU2002225772A1 AU2002225772A AU2577202A AU2002225772A1 AU 2002225772 A1 AU2002225772 A1 AU 2002225772A1 AU 2002225772 A AU2002225772 A AU 2002225772A AU 2577202 A AU2577202 A AU 2577202A AU 2002225772 A1 AU2002225772 A1 AU 2002225772A1
Authority
AU
Australia
Prior art keywords
treating
therapeutic agents
methods
amyloidogenic disease
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002225772A
Inventor
Malcolm L. Gefter
Michael Gosselin
David I. Israel
John L. Joyal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praecis Pharmaceuticals Inc
Original Assignee
Praecis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praecis Pharmaceuticals Inc filed Critical Praecis Pharmaceuticals Inc
Publication of AU2002225772A1 publication Critical patent/AU2002225772A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The present invention provides therapeutic agents suitable for treating an amyloidogenic disorder, as well as pharmaceutical compositions comprising the therapeutic agents and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an amyloidogenic disorder, e.g., Alzheimer's disease, in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.
AU2002225772A 2000-11-27 2001-11-27 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease Abandoned AU2002225772A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US25330200P 2000-11-27 2000-11-27
US60/253,302 2000-11-27
US25019800P 2000-11-29 2000-11-29
US60/250,198 2000-11-29
US25718600P 2000-12-20 2000-12-20
US60/257,186 2000-12-20
PCT/US2001/044581 WO2002042462A2 (en) 2000-11-27 2001-11-27 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease

Publications (1)

Publication Number Publication Date
AU2002225772A1 true AU2002225772A1 (en) 2002-06-03

Family

ID=27400294

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002225772A Abandoned AU2002225772A1 (en) 2000-11-27 2001-11-27 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease

Country Status (10)

Country Link
US (1) US20020133001A1 (en)
EP (1) EP1346041B1 (en)
JP (1) JP2004534511A (en)
AT (1) ATE355374T1 (en)
AU (1) AU2002225772A1 (en)
DE (1) DE60126980T2 (en)
DK (1) DK1346041T3 (en)
ES (1) ES2283463T3 (en)
PT (1) PT1346041E (en)
WO (1) WO2002042462A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
EP1457500A1 (en) * 2003-03-14 2004-09-15 University of Zurich Soluble hybrid prion proteins and their use in the diagnosis, prevention and treatment of transmissible spongiform encephalophathies
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US20060069010A1 (en) * 2003-10-17 2006-03-30 Senicure Llc Detoxification depot for Alzheimer's disease
WO2005059100A2 (en) * 2003-12-12 2005-06-30 New York University Methods and compositions relating to cystatin c
JP2007528374A (en) * 2004-03-02 2007-10-11 セレクター，リミティド ライアビリティ カンパニー Phospholipid analogs as DIAPEUTIC® agents and methods thereof
AR052051A1 (en) 2004-12-15 2007-02-28 Neuralab Ltd AB HUMANIZED ANTIBODIES USED TO IMPROVE COGNITION
GB2424886A (en) * 2005-04-04 2006-10-11 Dxs Ltd Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations
US20070092508A1 (en) * 2005-10-21 2007-04-26 Recombiant Technologies, Llc Detoxification depot for Alzheimer's disease
DK1954718T3 (en) 2005-11-30 2014-12-15 Abbvie Inc Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
EP1976877B2 (en) 2005-11-30 2016-10-05 AbbVie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
GB0605735D0 (en) * 2006-03-22 2006-05-03 Immunobiology Ltd Composition and method for mediating an immune response
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
GB0615266D0 (en) * 2006-08-01 2006-09-06 Immunobiology Ltd Composition and method for mediating an immune response
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5554528B2 (en) * 2009-09-08 2014-07-23 国立大学法人 岡山大学 Novel amyloid β aggregate-binding peptide and method for testing amyloid disease using the novel amyloid β aggregate-binding peptide
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CN104380110A (en) * 2012-04-05 2015-02-25 于利希研究中心有限公司 Method for treating blood, blood products and organs
CN107652356A (en) * 2012-04-05 2018-02-02 于利希研究中心有限公司 The polymer of D peptides comprising multivalence combination amyloid beta protein and its application
DE102012108598A1 (en) 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH New D3-D enantiomeric peptides derived from D3 and their use
FR3012453B1 (en) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement CHIMERIC PROTEIN FOR THE TREATMENT OF AMYLOSIS
PL417159A1 (en) 2016-05-11 2017-11-20 Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego Conjugates of prion protein with dendrimers for application in treatment of Alzheimer disease
CN113398253B (en) * 2021-05-14 2023-01-24 北京化工大学 Inhibitors of beta 2 microglobulin aggregation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635600A (en) * 1986-07-07 1997-06-03 Trustees Of Dartmouth College Bifunctional and heteroantibodies specific for the high affinity Fc receptor for immunoglobulin G on human mononuclear phagocytes
US6071517A (en) * 1986-07-07 2000-06-06 Medarex, Inc. Bispecific heteroantibodies with dual effector functions
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5200178A (en) * 1988-02-26 1993-04-06 The General Hospital Corporation Method for tumor detection
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5981194A (en) * 1992-07-10 1999-11-09 University Of British Columbia Use of p97 and iron binding proteins as diagnostic and therapeutic agents
WO1996028471A1 (en) * 1995-03-14 1996-09-19 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5817789A (en) * 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US5786187A (en) * 1995-09-21 1998-07-28 The Research Foundation Of State University Of New York Method for reducing neuronal degeneration associated with seizure
US6071493A (en) * 1996-09-20 2000-06-06 Baylor College Of Medicine Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules

Also Published As

Publication number Publication date
DE60126980D1 (en) 2007-04-12
JP2004534511A (en) 2004-11-18
WO2002042462A2 (en) 2002-05-30
EP1346041A2 (en) 2003-09-24
DK1346041T3 (en) 2007-07-02
WO2002042462A3 (en) 2003-06-19
PT1346041E (en) 2007-06-05
ES2283463T3 (en) 2007-11-01
ATE355374T1 (en) 2006-03-15
EP1346041B1 (en) 2007-02-28
DE60126980T2 (en) 2007-11-08
US20020133001A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
CA2426703A1 (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
CA2427227A1 (en) Lactam compound
BRPI0108977B8 (en) azacyclic compounds, pharmaceutical composition and use of a compound or pharmaceutically acceptable salt thereof
BG106586A (en) Pyrazolopyramidines as therapeutic agents
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
DE60316779D1 (en) THIADIAZOLYLPIPERAZINE DERIVATIVES SUITABLE FOR THE TREATMENT OF BZW. PREVENTION OF PAIN
TW200518753A (en) Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
BR0210122A (en) Compound or a pharmaceutically acceptable salt thereof, method for treating or preventing a disease, use of the compound or salt thereof, and method for preparing the same
PT1317419E (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
MY119375A (en) Treatment of tinnitus using neuroprotective agents
WO2005056524A3 (en) Therapeutic agents useful for treating pain
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
HUP0302635A2 (en) Phospholipid derivatives of valproic acid and mixtures thereof
SE0102055D0 (en) New Compounds
SE0102440D0 (en) New compound
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
AU2003277280A1 (en) Biphenyls and fluorenes as imaging agents in alzheimer's disease
EE200100689A (en) Use of IL6RIL6 Chimera for the preparation of a medicament for the treatment of neurological diseases, and pharmaceutical composition
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
GEP20043377B (en) Pharmaceutical Complex
IL164317A0 (en) Statin therapy for enhancing cognitive maintenance